CD137 Agonist Antibody - Pipeline Insight, 2022

“CD137 Agonist Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in CD137 Agonist Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

CD137 Agonist Antibody Understanding

CD137 Agonist Antibody: Overview
CD137, also known as 4-1BB, has long been known as a target of interest for cancer. It is a costimulatory immunoreceptor and a member of the TNF-receptor family. The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Agonistic anti-CD137 antibody enhances anti-cancer immunity to protect from solid tumors. This outcome is due to an active effect of cytotoxic T cells, NK cells, and macrophages by this antibody.

"CD137 Agonist Antibody - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CD137 Agonist Antibody pipeline landscape is provided which includes the disease overview and CD137 Agonist Antibody treatment guidelines. The assessment part of the report embraces, in depth CD137 Agonist Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CD137 Agonist Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence CD137 Agonist Antibody R&D. The therapies under development are focused on novel approaches to treat/improve CD137 Agonist Antibody.

CD137 Agonist Antibody Emerging Drugs Chapters
This segment of the CD137 Agonist Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CD137 Agonist Antibody Emerging Drugs
• Utomilumab: Pfizer
Utomilumab (PF-05082566) is a human IgG2 antibody agonist that targets the extracellular domain of 4-1BB (CD137), which is a co-stimulatory receptor expressed on activated T cells. The drug is being studied in Phase II clinical trials for the treatment of patients with Breast cancer.

• LVGN6051: Lyvgen
LVGN6051 specifically binds human CD137 (4-1BB) and activates its signaling only when the engineered Fc of LVGN6051 engages Fc?RIIB. In contrast to the first generation CD137 agonist antibodies that entered clinic, LVGN6051 has bi-specificity for CD137 and Fc?RIIB. Lyvgen has initiated a Phase I clinical trial in October of 2019.

• AGEN2373: Agenus, Inc.
AGEN2373 is a CD137 Agonist Antibody designed to leverage optimal CD137 and Fc?R co-targeting to promote antitumor immunologic effects. The drug is currently in Phase I stage of development for the treatment of solid tumors.
Further product details are provided in the report……..

CD137 Agonist Antibody: Therapeutic Assessment
This segment of the report provides insights about the different CD137 Agonist Antibody drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in CD137 Agonist Antibody
There are approx. 15+ key companies which are developing the therapies for CD137 Agonist Antibody. The companies which have their CD137 Agonist Antibody drug candidates in the most advanced stage, i.e. phase II include, Pfizer.
• Phases
This report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
CD137 Agonist Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CD137 Agonist Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD137 Agonist Antibody therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD137 Agonist Antibody drugs.

CD137 Agonist Antibody Report Insights
• CD137 Agonist Antibody Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CD137 Agonist Antibody Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing CD137 Agonist Antibody drugs?
• How many CD137 Agonist Antibody drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD137 Agonist Antibody?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD137 Agonist Antibody therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CD137 Agonist Antibody and their status?
• What are the key designations that have been granted to the emerging drugs?